Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar;10(1):81-7.
doi: 10.1007/s12311-010-0232-3.

Superior cerebellar peduncle atrophy in Friedreich's ataxia correlates with disease symptoms

Affiliations

Superior cerebellar peduncle atrophy in Friedreich's ataxia correlates with disease symptoms

Hamed Akhlaghi et al. Cerebellum. 2011 Mar.

Abstract

Friedreich's ataxia (FRDA) is the most common early onset inherited ataxia with clinical manifestations, including gradual progression of unremitting cerebellar-sensory ataxia, peripheral sensory loss, loss of lower limb tendon reflexes and hypertrophic cardiomyopathy. Although atrophy of the superior cerebellar peduncle (SCP) has been reported in several magnetic resonance imaging (MRI) studies of FRDA, the relationship of SCP changes to genetic and clinical features of FRDA has not been investigated. We acquired T1-weighted MRI scans in 12 right-handed individuals with FRDA, homozygous for a GAA expansion in intron 1 of FXN, as well as 13 healthy age-matched controls. The corrected cross-sectional areas of the right (left) SCP in the individuals with FRDA (R, 20 ± 7.9 mm(2); L, 25 ± 5.6 mm(2)) were significantly smaller than for controls (R, 68 ± 16 mm(2); L, 78 ± 17 mm(2)) (p < 0.001). The SCP volumes of individuals with FRDA were negatively correlated with Friedreich's ataxia rating scale score (r = -0.553) and disease duration (r = -0.541), and positively correlated with the age of onset (r = 0.548) (p < 0.05). These findings suggest that structural MR imaging of the SCP can provide a surrogate marker of disease severity in FRDA and support the potential role of structural MRI as a biomarker in the evaluation of neurodegenerative diseases and therapies.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Neuroimage. 2008 Mar 1;40(1):19-25 - PubMed
    1. Stat Methods Med Res. 1999 Jun;8(2):135-60 - PubMed
    1. J Neurosci. 2003 Sep 10;23(23):8432-44 - PubMed
    1. Science. 1996 Mar 8;271(5254):1423-7 - PubMed
    1. J Neurol. 2010 May;257(5):782-91 - PubMed

Publication types

LinkOut - more resources